TRB-061: A ‘Next-Gen’ Treg Augmenter for I&I Disea

Time: 9:30 am
day: Conference Day One


  • TNFR2 is highly expressed on immunosuppressive Treg in inflamed tissues.
  • TRB-061, a TNFR2-selective agonist, shows potent in vitro and in vivo Treg augmentation, providing protection in preclinical models of inflammation.
  • Our ‘Deep Biology Platform’ revealed the molecular details of TNFR2 agonism on Treg allowing for the design of an optimal agonist molecule and suggests differentiated clinical opportunities in inflammatory and autoimmune diseases